NexImmune, Inc. announced that, in order to reduce its cash expenditures while continuing to pursue its existing strategic plan, its Board of Directors approved and its management is implementing an approximately 53% reduction in workforce, designed to reduce costs and extend the Company?s cash. The realignment will reduce the Company?s workforce from 47 to 22 full-time employees as of September 5, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.06 USD | +1.66% | -3.80% | +37.84% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 16 | NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+37.84% | 4.2M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- NEXI Stock
- News NexImmune, Inc.
- NexImmune, Inc. Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy